Geneseeq Technology Inc., along with our clinical collaborators will present new data at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, which will held from May 29 to May 31. Twenty of our studies have been selected by the ASCO committee, including one oral presentation and eight poster presentations covering topics on advances in genomic profiling technology, novel biomarker and cancer genomic discoveries. Geneseeq will also participate in the virtual exhibit that launches on May 29 with the Virtual Scientific Program, and continue to be available online until the end of August. Talk to our exhibit staff in real-time for more information about our products and services.
Highlights of our studies include:
- Avoiding unnecessary genetic testing of circulating tumor DNA (ctDNA) from the cerebrospinal fluid of patients with metastatic tumors, by utilizing a predictive regression model based on phenotypic characteristics of brain metastases (Oral #2507);
- Genomic profiling of circulating tumor DNA from liquid biopsy samples using Geneseeq’s targeted panels to help with minimal residual disease monitoring and detecting cancer recurrence/metastasis in early stage colorectal and lung cancer (Poster #4079 and #3537);
- Utilizing Geneseeq’s 425-gene panel, GeneseeqPrime®, in a cohort of 8619 lung cancer patients to help inform differential genomic features and evolutionary patterns in metastatic tumors from primary lung tumors that show metastasis in a site-specific manner (Poster #9584);
- in silico and structural insights from a molecular dynamic simulation-based model of the mutant EGFR protein helps predict its sensitivity to EGFR TKI in rare EGFR mutations (Poster #9531);
- Discovery of ERBB2 exon 16-skipping alteration as a novel resistance mechanism against EGFR TKI treatment in lung cancer, highlighting the importance of comprehensive genomic profiling in revealing drug-resistance mechanisms (Poster #9528);
- Kinome fusions and the genomic instability landscape of lung cancer (Poster #9534).
The following is a list of our studies that will be presented at the meeting. To access full abstracts for more details, please visit: meetinglibrary.asco.org.
| Abstract # | Title |
| Oral Presentation | |
| 2507 |
Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid |
| Poster Presentation | |
| 9584.350 |
Genomic characterization of metastatic lung cancers |
| 9534.300 |
Distinct genomic instability landscape of lung adenocarcinoma associated with treatment and metastasis |
| 9620.386 |
Genomic characterization and outcome evaluation of kinome fusions in a large non-small cell lung cancer population |
| 4079.71 |
Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer |
| 3537.267 |
Circulating tumor DNA dynamics to predict cancer recurrence/metastasis in Chinese pathologic stage I lung adenocarcinoma |
| 9528.294 |
Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) |
| 9531.297 |
Identification and in silico structural insights of rare recurrent EGFR mutations as resistance mechanisms to osimertinib in EGFR-mutated lung cancer |
| 2556.47 |
Ibrutinib-based combination therapy exhibited therapeutic benefit in newly diagnosed primary central nervous system lymphoma |
| Online Publication | |
| e16080 |
DNA methylation signatures predicting liver metastasis of colorectal cancer: A proof-of-concept pilot study |
| e14538 |
Genomic profiling identified novel prognostic biomarker in Chinese glioma patients |
| e21578 |
Genomic correlates and classification of PD-L1 status in non-small cell lung cancer |
| e13520 |
Genomic landscape and clinicopathological characteristics of lung cancer in young Chinese patients |
| e13662 |
Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies |
| e13528 |
Genomic and epigenomic profiles to distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer |
| e21036 |
Characterizing the molecular and immunological features of lung micropapillary adenocarcinoma |
| e13522 |
Identification of kinase domain duplications across diverse cancer types in Chinese population by comprehensive genomic profiling (CGP) |
| e13523 |
Incidence of mutated DNA damage response pathway and clinically actionable alterations in Chinese patients with unknown primary tumor revealed by comprehensive genomic profiling |
| e16112 |
Circulating tumor DNA to monitor treatment response and investigate resistance mechanism in BRAF inhibitor treated colorectal cancer patients |
| e21068 |
An exploratory study of PD-1 inhibitor for high-risk multiple ground-glass nodules (mGGNs) in synchronous stage I non-small cell lung cancer patients |
About Geneseeq
Geneseeq is a research-driven company providing cutting-edge NGS technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type specific gene panels to help match a patient to the optimal treatment, including targeted therapy and immunotherapy. We have 1000+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. Our headquarters are located in both Canada and China. Our CAP/CLIA accredited Chinese site is equipped with multiple advanced NGS sequencing platforms and has sequenced 310,000+ clinical samples. For more information, please visit na.geneseeq.com or follow Geneseeq on Linkedin and Twitter.